Bristol Myers Squibb vs GSK
Bristol Myers Squibb and GSK are similar in size: $48.19bn and $43.09bn of revenue in their latest fiscal years. GSK grew faster (7.5% against -0.2%). GSK kept more of each dollar of sales as profit: a net margin of 17.5% against 14.6%. GSK carries less debt relative to equity (108.2% against 254.9%).
| Latest fiscal year | Bristol Myers SquibbBMY, 2025 | GSKGSK, 2025 |
|---|---|---|
| Revenue | $48.19bn | $43.09bn |
| Revenue growth | -0.2% | 7.5% |
| Net income | $7.05bn | $7.54bn |
| Operating margin | — | 24.3% |
| Net margin | 14.6% | 17.5% |
| Return on equity | 40.5% | 38.5% |
| Free cash flow | $12.85bn | $8.43bn |
| Cash | $10.21bn | $4.57bn |
| Total debt | $47.09bn | $23.83bn |
| Debt to equity | 254.9% | 108.2% |
| Dividend per share | $2.49 | — |
| Dividend yield | 4.0% | — |
| Share buybacks | $0 | $1.82bn |
| Employees | 32,500 | — |
| Market value | $126.73bn | $100.19bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 77 (Strong) | — |
| Insider trades, 12 months | 0 buys, 4 sales | 0 buys, 0 sales |